基线[18F]FDG PET/CT对复发/难治性B细胞急性淋巴细胞白血病髓外病变的特征描述及CAR-T治疗预后价值
回顾性纳入81例接受CAR-T治疗前行[18F]FDG PET/CT的复发/难治性B细胞急性淋巴细胞白血病患者,描述非中枢神经系统髓外病变特征并评估代谢参数的预后价值。中位随访23.7个月,多因素分析示血红蛋白和SUVmax(截断值7.0)为无进展生存和总生存的独立预后因素。
要点
- 非中枢神经系统髓外病变最常累及淋巴结、脾和肾。
- SUVmax以7.0为截断值,高于阈值者无进展生存和总生存显著缩短。
- 血红蛋白异常者无进展生存和总生存较血红蛋白正常者显著缩短。
核心结论
- [18F]FDG PET/CT可有效显示B细胞急性淋巴细胞白血病患者的髓外浸润,这些非中枢神经系统髓外病变与临床结局相关。
- SUVmax是无进展生存和总生存的有价值预测生物标志物。
研究设计与样本
- 回顾性纳入接受CAR-T细胞治疗前行[18F]FDG PET/CT的复发/难治性B细胞急性淋巴细胞白血病患者,共81例。
- 使用LIFEx软件以最大摄取值41%为阈值半自动分割病灶,汇总FDG高摄取病灶解剖位置以描述非中枢神经系统髓外病变特征。
- 收集FDG PET/CT代谢参数(SUVmax、MTV、TLG)及选定的临床和实验室特征,将变量分类为两组进行生存分析,采用Kaplan-Meier法估计无进展生存和总生存。
主要发现
- 最常观察到的非中枢神经系统髓外病变累及淋巴结、脾和肾。
- 中位随访23.7个月,多因素分析确定血红蛋白和SUVmax(截断值7.0)为无进展生存和总生存的独立预后因素。
- 血红蛋白异常者较血红蛋白正常者无进展生存和总生存显著缩短(中位无进展生存:13.5个月 vs 未达到,P=0.004;中位总生存:48.0个月 vs 未达到,P=0.010)。
- SUVmax高于阈值者较低于阈值者无进展生存和总生存显著缩短(中位无进展生存:9.1个月 vs 未达到,P≤0.001;中位总生存:27.0个月 vs 50.8个月,P=0.020)。
关键数值与推荐
- 病灶分割阈值:最大摄取值41%。
- SUVmax截断值:7.0。
- 血红蛋白异常者中位无进展生存13.5个月 vs 血红蛋白正常者未达到(P=0.004);中位总生存48.0个月 vs 未达到(P=0.010)。
- SUVmax高于7.0者中位无进展生存9.1个月 vs 低于7.0者未达到(P≤0.001);中位总生存27.0个月 vs 50.8个月(P=0.020)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to characterize the non-central nervous system extramedullary disease (non-CNS EMD) in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and to evaluate the prognostic value of metabolic parameters derived from [18F]FDG PET/CT imaging. METHODS: Patients with r/r B-ALL who received chimeric antigen receptor (CAR)-T cell therapy and underwent [18F]FDG PET/CT before CAR-T cell therapy were retrospectively enrolled. Lesions were semi-automatically segmented using LIFEx software, based on a threshold of 41% of the maximal uptake value. The anatomical locations of FDG-avid lesions were summarized to delineate the characteristics of non-CNS EMD. Furthermore, metabolic parameters from FDG PET/CT (SUVmax, MTV, and TLG) as well as selected clinical and laboratory features were collected. These variables were categorized into two groups for survival analysis. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. RESULTS: A total of 81 B-ALL patients were included in this study. The most frequently observed non-CNS EMD lesions involved the lymph node, spleen, and kidney. After a median follow-up time of 23.7 months, multivariate analysis identified hemoglobin (Hb) and SUVmax (with a cut-off value of 7.0) as independent prognostic factors for PFS and OS. Patients with abnormal Hb levels exhibited significantly shorter PFS and OS compared to those with normal Hb levels (median PFS: 13.5 months vs. not reached, P = 0.004; median OS: 48.0 months vs. not reached, P = 0.010). Similarly, patients with SUVmax above the threshold had significantly reduced PFS and OS compared to those below the threshold (median PFS: 9.1 months vs. not reached, P ≤ 0.001; median OS: 27.0 months vs. 50.8 months, P = 0.020). CONCLUSION: [18F]FDG PET/CT effectively visualizes extramedullary infiltration in patients with B-ALL, and these non-CNS EMD lesions were also associated with clinical outcomes. SUVmax serves as a valuable predictive biomarker for both PFS and OS.
引用
- Yao X, Wei L, Wang H, et al. Baseline [18F]FDG PET/CT characterization of extramedullary disease and prognostic value in relapsed/refractory B-cell acute lymphoblastic leukemia treated with CAR-T cells. Eur J Nucl Med Mol Imaging. 2025. PMID: 40974407. doi:10.1007/s00259-025-07562-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。